ATAGI statement on the intradermal use of Imojev Japanese encephalitis vaccine

ATAGI has reviewed the evidence on the intradermal (ID) administration of Japanese encephalitis (JE) vaccines and considered the potential use of Imojev as a dose-sparing mechanism, in the context of the risk of future outbreaks, expanded eligibility in risk areas, and ongoing supply considerations.

Downloads

ATAGI statement on the intradermal use of Imojev Japanese encephalitis vaccine

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date:
Publication type:
Guideline
Audience:
Health sector
Language:
English

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.